Contrast Agents and Radiopharmaceuticals | Market Insights | US | 2021
The COVID-19 pandemic will have a significant impact on the US diagnostic imaging market in the short term. Once the market stabilizes, however, the contrast agents and radiopharmaceuticals market in US will see modest growth through 2029 driven by a growing aging population, increases in health risk factors like poor lifestyle, and adoption of new technology due to favorable regulatory changes. However, overall market expansion will be hindered by a saturated installed base of large imaging systems as well as consolidation of hospitals.
Growth in the US market for contrast agents and radiopharmaceuticals will be driven by the expanded use of imaging agents in CEUS and PET procedures. However, the market will be somewhat limited by the continued concern over gadolinium and radiation exposure in certain modalities, while the shift to value-based care will hinder the use of some procedures while supporting the use of those that provide the most accuracy and clarity of visualization.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in the US across a 10-year period.
